Moreover, inhibition of Matrix Metalloproteinase-9 (MMP-9) by lipocalin 2 (LCN2) can reduce almonertinib resistance, suggesting that the LCN2/MMP-9 axis might offer a potential strategy for addressing drug resistance in lung adenocarcinoma [239]. This evidence concerns the gene LCN2 and lung adenocarcinoma.